Skip to content
TrialMatch
Sign up
Recruiting

European Myeloma Network (EMN) Sample Project

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

Condition
Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma, MGUS
Tested
storage of biological samples
Sponsor
European Myeloma Network B.V.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 7

  • Minimum age: 18 years
  • Study condition: Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma, MGUS
  • Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD)
  • Subjects are ≥ 18 years old.
  • Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures.
  • Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and
  • subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.

Exclusion 3

  • Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care).
  • Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events.
  • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.

Where

41 sites, 41 recruiting

Alfred Hospital

Melbourne, Australia

Recruiting

KUK Linz

Linz, Austria

Recruiting

Medical University Vienna

Vienna, Austria

Recruiting

Department of Haematology UZ Leuven Gasthuisberg

Leuven, Belgium

Recruiting

Nemocnice Havířov

Havířov, Czechia

Recruiting

Nemocnice Nový Jičín

Nový Jičín, Czechia

Recruiting

and 35 more sites on ClinicalTrials.gov

Contact

Potential match only. Final eligibility is determined by the study team.